Agios: 'Sell' On Tebapivat Setback LR-MDS And Competitive PK Activator Drug Class (AGIO)

Agios Pharmaceuticals, Inc. a Sell amid tebapivat setback & tougher PK activator competition; see risks, SCD catalysts, and cash runway. Click for an AGIO update.

Read on WOBR AI →